Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia - 21/08/11
, Tineke J. Smilde, MD, PhD b, Mieke D. Trip, MD, PhD a, Anton F.H. Stalenhoef, MD, PhD b, John J.P. Kastelein, MD, PhD aRésumé |
In the 2-year Atorvastatin versus Simvastatin on Atherosclerosis Progression extension study, patients with familial hypercholesterolemia who continued to take atorvastatin 80 mg for an additional 2 years had complete arrest of the progression of mean carotid intima-media thickness (0.89 mm at the start vs 0.90 mm at the end of the study, p = 0.58). In contrast, patients previously taking simvastatin 40 mg had significant regression of intima-media thickness (0.95 mm at the start vs 0.92 mm at the end of the study, p = 0.01). Therefore, both placebo- and statin-treated patients with familial hypercholesterolemia are best treated with high-dose atorvastatin, a therapeutic regimen that induces atherosclerosis regression and is safe and well tolerated over a 4-year period.
Le texte complet de cet article est disponible en PDF.| This study was supported by Pfizer, Capelle aan de Yssel, The Netherlands. |
Vol 95 - N° 2
P. 264-266 - janvier 2005 Retour au numéro
Article précédent
- Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries
- Alf Inge Larsen, P. Diane Galbraith, William A. Ghali, Colleen M. Norris, Michelle M. Graham, Merril L. Knudtson, APPROACH Investigators *
- Effect of medical and surgical weight loss on endothelial vasomotor function in obese patients
- Noyan Gokce, Joseph A. Vita, Marie McDonnell, Armour R. Forse, Nawfal Istfan, Maria Stoeckl, Izabella Lipinska, John F. Keaney, Caroline M. Apovian
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?